Portal de Periódicos da CAPES

Safety of vedolizumab in the treatment of Crohn’s disease and ulcerative colitis

2015; Taylor & Francis; Volume: 14; Issue: 9 Linguagem: Inglês

10.1517/14740338.2015.1063612

1744-764X

Matilda Hagan, Raymond K. Cross,

Pregnancy and Medication Impact

Introduction: Vedolizumab is the latest FDA-approved anti-integrin therapy for treatment of moderate-to-severe inflammatory bowel disease (IBD). The safety and efficacy of vedolizumab have been studied in short-term clinical trials.